Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

Abstract

Aims Percutaneous coronary intervention (PCI) of a bifurcation lesion (BL) is still associated with poorer clinical outcomes when compared with PCI of a non-BL. Therefore, several dedicated coronary bifurcation stents, such as the Tryton Side Branch Stent™ (Tryton Medical, Durham, NC, USA), were developed to improve clinical outcomes. We investigated 6-month clinical outcomes after placement of a Tryton stent in 91 patients treated for 93 BLs in our centre. Methods and results All consecutive patients who have undergone PCI of a BL treated with the Tryton stent in our centre were included. Outcomes were defined as any death, cardiac death, myocardial infarction (MI), any revascularisation, ischaemia-driven target vessel revascularisation (TVR), ischaemia-driven target lesion revascularisation (TLR), stent thrombosis, and target vessel failure (TVF; composite of cardiac death, MI, and ischaemia-driven TVR). Event rates were estimated using the Kaplan-Meier method. Thirty-eight (42 %) patients with acute coronary syndrome (ACS) were included (16 % ST-segment elevation MI (STEMI)). The 6-month event rates were 5.4 % (death), 4.3 % (cardiac death), 2.2 % (MI), 4.5 % (any revascularisation), 4.5 % (TVR), 4.5 % (TLR) and 9.7 % (TVF). ConclusionIn a real-world all-comers single-centre registry, the use of the Tryton Side Branch Stent was associated with acceptable procedural and promising clinical outcomes at 6 months, including ACS and STEMI patients.

First report on long‐term clinical results after treatment of coronary bifurcation lesions with the Tryton dedicated bifurcation stent

“…Previous observational studies on the Tryton stent consistently showed six‐ to twelve‐month TLR rates of ∼4% . The current report showed that these results are sustainable up to two years of follow‐up, TLR rate increased from 5.8% at one‐year up to 9.2% at two years.…”

“…Clinical outcomes were reported as cardiac death, any myocardial infarction (MI), target vessel revascularization (TVR), target lesion revascularization (TLR), definite or probable stent thrombosis (ST), and target vessel failure (TVF), defined as the composite of cardiac death, any MI, and TVR. All outcome definitions were similar to our previous publication , except that for the current analysis, TLR was further stratified to TLR of the MB and/or TLR of the SB.…”

“…The Tryton Side Branch Stent™ (Tryton Medical, Durham, NC) has been developed to improve clinical outcomes after percutaneous coronary intervention (PCI) of bifurcation lesions . Previous observational studies have shown promising procedural and clinical results when using this device in combination with a drug‐eluting stent (DES) in the main branch (MB) during PCI of bifurcation lesions . However, these studies have a limited follow‐up of 6–12 months and until to date data beyond 1 year are lacking.…”

“…However, these studies have a limited follow‐up of 6–12 months and until to date data beyond 1 year are lacking. Therefore, clinical outcomes at 1 and 2 years were evaluated of 91 consecutive patients treated with the Tryton stent in our own center .…”

The Tryton Side Branch Stent™ for the treatment of coronary bifurcation lesions

“…To improve clinical outcomes after PCI of coronary bifurcation lesions, several dedicated bifurcation devices, such as the Tryton Side-Branch Stent TM (Tryton Medical, Durham, NC), have been developed. Previous smaller registry studies [10][11][12][13] and a patient pooled analysis [14] with this stent in de novo bifurcation lesions showed promising procedural and clinical outcomes. Tryton is a side branch first bare-metal stent and its specific design, with a minimal amount of metal in the proximal main branch zone, facilitates easy delivery of a regular drug-eluting stent (DES) in the main branch [15].…”